Completed PHASE3 INTERVENTIONAL 2-arm NCT01675076

Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events (BRUISECONTROL2)

A Randomized Controlled Trial to Investigate Whether a Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at the Time of Device Surgery, in Patients With Moderate to High Risk of Arterial Thrombo-embolic Events, Leads to a Reduction in the Incidence of Clinically Significant Hematoma

Sponsor: Bayer

Conditions Hematoma

Interventions Apixaban Dabigatran Rivaroxaban

Updated 10 times since 2017 Last updated: Oct 2, 2019 Started: Jan 31, 2013 Primary completion: Oct 31, 2017 Completion: May 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01675076, this PHASE3 trial focuses on Hematoma and remains completed. Sponsored by Bayer, it has been updated 10 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

Jul 2018 — Nov 2019 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jun 2018 — Jul 2018 [monthly]

Active Not Recruiting PHASE3
Aug 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jun 2017 — Aug 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Jun 2017 [monthly]

Recruiting PHASE3

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
Heart and Stroke Foundation of Canada
Ottawa Heart Institute Research Corporation

Data source: Ottawa Heart Institute Research Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Calgary, Canada , Edmonton, Canada , Hamilton, Canada , Montreal, Canada , Nahariya, Israel , Newmarket, Canada , Ottawa, Canada , Québec, Canada , Sherbrooke, Canada , Toronto, Canada and 1 more location